Sugi Predict

Sugi Predict / Compounds / SCHEMBL433223

SCHEMBL433223

SCHEMBL433223

CC(C)(C)OC(=O)N1C[C@H](O[Si](C)(C)C(C)(C)C)CC1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ CHRM3 P20309 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ NR1H2 P55055 1/20 0.33
▸ ELANE P08246 1/20 0.32
▸ PDE4A P27815 1/20 0.31
▸ PDE4B Q07343 1/20 0.31
▸ PDE4C Q08493 1/20 0.31
▸ PDE4D Q08499 1/20 0.31
▸ KDM1A O60341 1/20 0.31
▸ DDB1 Q16531 1/20 0.31
▸ CRBN Q96SW2 1/20 0.31
▸ GPR119 Q8TDV5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL449025 1.00 CHRM2 (0.35) CHRM2CHRM1CHRM3KDM4EMAPT
SCHEMBL2133453 1.00 CHRM2 (0.35) CHRM2CHRM1CHRM3KDM4EMAPT
SCHEMBL26663582 0.88 CHRM2 (0.35) CHRM2CHRM1CHRM3KDM4EMAPT
SCHEMBL31513902 0.86 PDE4A (0.36) CHRM2CHRM1CHRM3KDM4EMAPT
SCHEMBL18581920 0.85 POLB (0.34) MEN1KMT2A
SCHEMBL2724433 0.85 POLB (0.34) MEN1KMT2A
SCHEMBL18581922 0.85 POLB (0.34) MEN1KMT2A
SCHEMBL6978858 0.82 USP2 (0.31) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL6978861 0.82 USP2 (0.31) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL17848943 0.81 SMN1; SMN2 (0.36) KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115490708-B Sulfonamide macrocyclic derivative, preparation method and application thereof 苏州亚盛药业有限公司 2025-01-24 — — CN disclosed
EP-4420732-A2 FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS CMG Pharmaceutical Co., Ltd. (KR) 2024-08-28 — — EP disclosed
US-20240228506-A1 RIPK1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2024-07-11 — — US disclosed
US-20240228506-A1 RIPK1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2024-07-11 — — US disclosed
US-20240208986-A1 PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2024-06-27 — — US disclosed
EP-3233863-B1 FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS CMG PHARMACEUTICAL CO LTD (KR) 2024-04-10 — — EP disclosed
EP-4329766-A1 RIPK1 INHIBITORS AND METHODS OF USE Merck Sharp & Dohme LLC (US) 2024-03-06 — — EP disclosed
EP-4329765-A1 PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF Merck Sharp & Dohme LLC (US) 2024-03-06 — — EP disclosed
EP-3674307-B1 MACROCYCLE CONTAINING AMINOPYRAZOLE AND PYRIMIDINE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2023-06-07 — — EP disclosed
US-20230112039-A1 PHARMACEUTICAL COMPOSITIONS AND THEIR USES BENEVOLENTAI BIO LIMITED (GB) 2023-04-13 — — US disclosed
EP-2678338-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2014-01-01 — — EP disclosed
US-20130331397-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2013-12-12 — — US disclosed
US-20130203776-A1 MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2013-08-08 — — US disclosed
EP-2614062-A1 IMIDAZO [1, 2]PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2013-07-17 — — EP disclosed
WO-2012116217-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2012-08-30 — — WO disclosed
US-20120065184-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2012-03-15 — — US disclosed
US-20120065184-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2012-03-15 — — US disclosed
US-20120065184-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2012-03-15 — — US disclosed
WO-2012034091-A1 IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2012-03-15 — — WO disclosed
WO-2000032605-A1 BI-PYRROLIDINYLVINL (CARBA) CEPHALOSPORINS F. HOFFMANN-LA ROCHE AG (CH) 2000-06-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203776-A1 MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K3 CHRM2 1627/4885CHRM1 1602/4885CHRM3 1919/4885
US-20240228506-A1 RIPK1 INHIBITORS AND METHODS OF USE RIPK1, RIPK2, RIPK3 CHRM2 4721/4885CHRM1 4741/4885CHRM3 4773/4885
US-20130331397-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS CNKSR1, BMP2K, RAF1 CHRM2 3902/4885CHRM1 3851/4885CHRM3 3320/4885
US-20120065184-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS TNK2, CNKSR1, BMP2K CHRM2 4506/4885CHRM1 4605/4885CHRM3 3928/4885
US-20230112039-A1 PHARMACEUTICAL COMPOSITIONS AND THEIR USES TNK2, DMPK, TPM3 CHRM2 1464/4885CHRM1 1663/4885CHRM3 1137/4885
US-20240208986-A1 PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF RIPK1, RIPK2, RIPK4 CHRM2 4633/4885CHRM1 4355/4885CHRM3 4723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.